5.4 Hematopoietic Progenitors

Why Hematopoietic Progenitors Are on the Blood Bank Specialist Exam

Many transfusion services, especially at academic and transplant centers, operate the apheresis and cellular processing laboratory that collects and prepares hematopoietic progenitor cell (HPC) products for transplant. The SBB exam tests collection sources, mobilization pharmacology, processing for ABO incompatibility, cryopreservation, and the regulatory framework that governs these products as a distinct category from routine transfusable components.

Sources of Hematopoietic Progenitor Cells

Mobilization for Peripheral Blood Collection

At steady state, few CD34+ progenitor cells circulate in peripheral blood. Granulocyte colony-stimulating factor (G-CSF, filgrastim), given daily for about 4-5 days, stimulates marrow proliferation and drives progenitor egress into the bloodstream. Plerixafor, a CXCR4 antagonist, blocks the SDF-1/CXCR4 signal that normally retains progenitors in the marrow niche, and is added for patients who mobilize poorly with G-CSF alone (often identified by a low pre-apheresis peripheral CD34+ count). Autologous mobilization sometimes combines chemotherapy with G-CSF ("chemo-mobilization") to both treat disease and mobilize progenitors simultaneously.

Apheresis Collection (Leukapheresis)

A continuous-flow cell separator processes blood at the mononuclear cell (buffy coat) interface to harvest CD34+ progenitors, using the same ACD-A anticoagulation and citrate-toxicity monitoring described for other apheresis products. Donors or patients with lower mobilization yields may require large-volume leukapheresis (LVL), processing 2-3 times the total blood volume to collect enough cells in a single session. The transplant dose target is generally 2-5 x 10^6 CD34+ cells/kg recipient body weight - 2 x 10^6/kg is widely treated as the minimum acceptable dose for timely engraftment, while allogeneic transplants and some protocols target 5 x 10^6/kg or higher for faster recovery - and collections sometimes span multiple days to reach that target.

Bone Marrow Harvest

Bone marrow is aspirated from the posterior iliac crest (occasionally anterior iliac crest or sternum) through multiple small-volume aspirations under general or regional anesthesia, targeting roughly 10-15 mL/kg of donor body weight to achieve an adequate nucleated cell dose for the recipient. The collected marrow is filtered to remove bone spicules and fat before further processing.

Processing HPC Products for ABO Incompatibility

Because HPC donors and recipients are matched primarily on HLA, not ABO, ABO-incompatible transplants are common and require specific graft processing:

Cryopreservation and Thawing

HPC products intended for storage are cryopreserved with dimethyl sulfoxide (DMSO), typically at a final concentration near 10%, which penetrates cells and prevents damaging intracellular ice crystal formation during controlled-rate freezing. Frozen products are stored in liquid nitrogen (liquid phase near -196C, or vapor phase near -150C) or in mechanical ultra-low freezers. Because DMSO is toxic at sustained exposure, products are rapidly thawed at the bedside in a 37C water bath immediately before infusion and infused promptly - "rapid thaw, rapid infuse." DMSO infusion reactions include nausea, flushing, a characteristic garlic-like taste or odor, and bradycardia or hypertension; premedication with antiemetics and antihistamines is common, especially for large-volume infusions such as double cord blood units.

Cord Blood Specifics

Cord blood is collected from the placenta and umbilical cord vessels shortly after delivery, posing no risk to the newborn or mother. Because cord blood units generally contain a lower total nucleated cell and CD34+ dose than marrow or apheresis products, dosing per kilogram is often the limiting factor for adult recipients, sometimes requiring two units combined (double cord blood transplant). Cord blood also tolerates greater HLA mismatch than marrow or peripheral blood grafts because cord lymphocytes are immunologically naive, which lowers graft-versus-host disease risk per degree of mismatch. Cord blood units are banked either publicly, for unrelated-donor use through registries, or privately, for family/directed use.

Quality and Potency Testing

Before release, HPC products undergo:

• Viability testing - 7-AAD or trypan blue dye exclusion, confirming the proportion of cells with intact membranes.
• CD34+ enumeration - flow cytometry using the ISHAGE gating protocol (sequential gating on CD45-dim, low side scatter, and CD34-positive events), the reference method for determining graft dose in cells/kg recipient weight.
• Colony-forming unit (CFU) assays (CFU-GM, BFU-E) - a functional backup potency measure, though slower (7-14 day culture) than flow cytometry.
• Sterility culture, required before infusion.

Regulatory Framework

The FDA regulates HPC products as Human Cells, Tissues, and Cellular/Tissue-Based Products (HCT/Ps) under 21 CFR Part 1271. Products that are minimally manipulated and intended for homologous use qualify as "361 products," regulated solely under Section 361 without premarket approval - most related-donor and autologous HPC products fall into this category. Products that undergo more than minimal manipulation, are intended for non-homologous use, or are combined with another article require an IND/BLA pathway as "351 products." Many transplant programs also pursue FACT (Foundation for the Accreditation of Cellular Therapy) accreditation for their collection, processing, and administration facilities.

Worked Example

A 70 kg recipient requires a target dose of 3 x 10^6 CD34+ cells/kg, or 2.1 x 10^8 CD34+ cells total. A single apheresis collection yields 1.5 x 10^8 CD34+ cells, short of the target, so a second collection day is needed to reach the required dose before the graft is released for infusion.

Common Traps

• Confusing major ABO incompatibility (red cell depletion needed) with minor ABO incompatibility (plasma/antibody depletion needed).
• Forgetting that DMSO toxicity, not cell fragility alone, is why HPC products are infused immediately after thawing.
• Treating all HPC products as regulated identically - the 361 versus 351 distinction depends on manipulation and homologous use, not simply on the source.